Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TXA709
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Boston University
Deal Size : $14.6 million
Deal Type : Funding
Details : Funding aims to develop Efflux Pump Inhibitors (EPIs), representing a new drug class designed to address a major mechanism of multi-drug-resistant (MDR) Pseudomonas aeruginosa bacteria.
Product Name : TXA709
Product Type : Other Small Molecule
Upfront Cash : $3.2 million
January 14, 2020
Lead Product(s) : TXA709
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Boston University
Deal Size : $14.6 million
Deal Type : Funding
Reset All
